TRML - Tourmaline Bio, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$48.50
DETAILS
HIGH:
$50.00
LOW:
$47.50
MEDIAN:
$48.00
CONSENSUS:
$48.50
UPSIDE:
1.08%
About Tourmaline Bio, Inc. (https://www.tourmalinebio.com)
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sandeep C. Kulkarni | Co-Founder, Chief Executive Officer & Director | 1982 | $848,250 USD |
| W. Bradford Middlekauff | Chief Business Officer, General Counsel & Corporate Secretary | 1962 | $582,250 USD |
| Ryan Robinson | Chief Financial Officer & Treasurer | 1989 | $575,855 USD |
| Kevin Johnson | Chief Regulatory Officer | 1965 | $555,835 USD |
| Don Fitch | Senior Vice President of Product Development | – | – |
| Dora Rau | Senior Vice President & Head of Quality | – | – |
| Emil deGoma | Senior Vice President of Medical Research | – | – |
| Famina Hemani | Vice President & Head of Pharmacovigilance | – | – |
| Gerhard Hagn | Senior Vice President and Head of Commercial & Business Development | – | – |
| John Walsh | Vice President & Head of Medical Affairs | – | – |
| Kimberly Piorkowski | Vice President of People, Culture & Compliance | – | – |
| Kristine Erickson | Vice President & TA Head of Ophthalmology, Medical Research | – | – |
| Susan Dana Jones | Chief Technology Officer | 1961 | – |